Kobayashi Pharma Crisis: Leaders Step Down Following Explosive Supplement Scandal

Nikkei has reported that Kobayashi Pharmaceutical's chairman and president will step down in response to delays in disclosing information and potential links between the company’s red yeast rice supplement and several health issues, including deaths. Chairman Kazumasa Kobayashi and President Akihiro Kobayashi, who are both part of the founding family, will be resigning. Satoshi Yamane, the Senior Executive Director, is anticipated to take over as president.

The red yeast rice supplement is under scrutiny for its possible connection to over 80 deaths, some of which are still being investigated. The board of directors is set to finalize these changes at their meeting on Tuesday. While Akihiro Kobayashi will relinquish his role as the company's representative, he will stay on as a director to address compensation claims related to the health risks associated with the supplement.

An independent legal team has been examining the events leading up to the initial disclosure of health issues and is set to release its findings on Tuesday. Their report is expected to critique the delay in Kobayashi Pharmaceutical's response, noting that it took over two months—from the first health case reported in mid-January to the company’s announcement on March 22. Additionally, the report will highlight that external directors were only informed right before the announcement. The legal team may also argue that the company hesitated to issue an early warning or recall the product.

In reaction to a separate evaluation revealing problems with the company's governance, the four external directors determined that a revamp of the management structure, including changes at the top, was necessary. The founding family of the company agreed to this overhaul. On March 29, the Japanese health ministry reported the presence of puberulic acid, a harmful substance from blue mold, in some batches of red yeast rice ingredients. Blue mold was also found in the culture room and air conditioning system at the Osaka facility where the ingredients were produced. The ministry is further investigating the potential toxicity of two other chemicals found in the product.